The international tumor-specific antigen cancer immunotherapy sector is currently experiencing a dynamic period of growth, fueled by significant progress in personalized medicine and a increasing understanding of the immune system's capability in combating cancers. Forecasts indicate a sustained expansion in the coming years, driven by therapeutic